A pivotal trial14 (SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53)) showed an amplified risk of HF (hazard ratio [HR] = 1.27; 95% CI, 1.07–1.51) associated with the DPP-4 inhibitor saxagliptin. Here, DPP4 is linked to hydrops fetalis.